Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | USP1 | O94782 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10006357 | 0.98 | GRIN2B (0.37) | ALDH1A1SMN1; SMN2NPC1RAB9ANPSR1 | |
| SCHEMBL10007381 | 0.91 | TSHR (0.38) | ALDH1A1SMN1; SMN2NPC1RAB9ANPSR1 | |
| SCHEMBL10261255 | 0.91 | PREP (0.36) | ALDH1A1GRIN2BPREP | |
| SCHEMBL10006624 | 0.90 | TSHR (0.43) | ALDH1A1NPC1NPSR1 | |
| SCHEMBL10006462 | 0.89 | GRIN1 (0.40) | MAOBGRIN2BGRIN1PREP | |
| SCHEMBL10007252 | 0.89 | ATM (0.39) | ALDH1A1MAOBGRIN2BGRIN1MAOA | |
| SCHEMBL10007296 | 0.88 | GRIN2B (0.43) | GRIN2BGRIN1 | |
| SCHEMBL10261397 | 0.88 | TSHR (0.41) | ALDH1A1SMN1; SMN2NPC1NPSR1 | |
| SCHEMBL10006678 | 0.87 | GRIN2B (0.37) | MAOBGRIN2BGRIN1USP1 | |
| SCHEMBL10006797 | 0.87 | ATM (0.39) | ALDH1A1MAOBGRIN2BGRIN1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2476682-B1 | 8-OXODIHYDROPURINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2017-04-26 | — | — | EP | disclosed |
| US-8735406-B2 | 8-oxodihydropurine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-2476682-A1 | 8-OXODIHYDROPURINE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-07-18 | — | — | EP | disclosed |
| US-20120172347-A1 | 8-OXODIHYDROPURINE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172347-A1 | 8-OXODIHYDROPURINE DERIVATIVE | FAAH, FAAH2, TPMT | ALDH1A1 50/4885SMN1; SMN2 2425/4885NPC1 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.